Aperio Clinical Outcomes
Aperio Clinical Outcomes is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Sponsor Acerta Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Daraxonrasib (RMC-6236) in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS(MUT) NSCLC
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome
Sponsor Telios Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor Celcuity Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Sponsor Kartos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Aperio Clinical Outcomes?
The 2026-10-09 snapshot links Aperio Clinical Outcomes to 15 distinct CTIS trials. Recorded services include Data management, Electronic data capture. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Aperio Clinical Outcomes?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Genetic and Congenital Disorders, Haematological Malignancies, Metabolic Disorders. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Aperio Clinical Outcomes conducted?
The linked trials record locations in 23 countries, including Spain, France, Italy, Germany, Czechia. These are trial locations, not confirmed office locations or countries where Aperio Clinical Outcomes delivered services.
What can this page tell me about Aperio Clinical Outcomes's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Aperio Clinical Outcomes. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Aperio Clinical Outcomes LLC